To explore the effects of Corylin and Corylifolinin in human small-cell lung cancer and its underlying mechanism

• Main Authors: Yu-Chieh Hu, 胡郁婕
• Other Authors: 林季千
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/6n896n

碩士 === 國立中興大學 === 生物醫學研究所 === 107 === Lung cancer is the leading cause of cancer deaths worldwide. Small cell lung cancer (SCLC) is the most common malignant of lung cancer because of the high growth fraction and metastasis in the early stage of the disease. Ally, SCLC is more responsive to chemotherapy than non-small cell lung cancer (NSCLC), therefore chemotherapy alone is usually the main treatment SCLC. The flavonoids of corylin and corylifolinin are known to have a variety of pharmacological effects such as antibacterial, anti-inflammatory and anti-cancer properties. However, there is no report on the antitumor effects of corylin and corylifolinin against human small cell lung cancer and the underlying molecular mechanisms of the antitumor activity of corylin and corylifolinin remain unclear. Therefore, in this study, the anticancer effects of corylin and corylifolinin were examined on H1688 human small cell lung cancer cells in vitro and in vivo. The possible molecular mechanisms responsible for its anticancer activity were also investigated. Our results indicated that corylin and corylifolinin inhibit SCLC cell H1688 growth and induced apoptosis by intrinsic and ex-trinsic pathway. Furthermore, corylifolinin triggered ER stress-dependent apoptosis, which could be mediated by activation of the JNK and p38 pathways and ROS overexpress. Finally, we also found that intraperitoneal administration of corylifolinin significantly suppressed the growth of s.c. H1688 xenografts. Together, these data provide insight into the molecular mechanisms underlying corylin but corylifolinin -induced apoptosis in SCLC cells, rendering these compounds a potential anticancer drug for small cell lung cancer.